Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02737072
Title A Study of LY2510924 and Durvalumab in Participants With Solid Tumors
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements No
Sponsors Eli Lilly and Company
Indications

Advanced Solid Tumor

Therapies

Durvalumab + LY2510924

Age Groups: adult
Covered Countries


No variant requirements are available.